Does the media favor ARCT or ALLO?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Allogene Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat Allogene Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ARCT or SVA?

Arcturus Therapeutics presently has a consensus target price of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ARCT or SVA?

Sinovac Biotech has higher revenue and earnings than Arcturus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcturus Therapeutics $42.35M 4.08 -$65.78M -$2.81 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Does the media refer more to MDXG or ARCT?

In the previous week, MiMedx Group had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat MiMedx Group's score of 0.32 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ARCT or AVTE?

Arcturus Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Arcturus Therapeutics (ARCT) Competitors

$6.08 -0.18 (-2.88%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$6.22 +0.14 (+2.35%)

As of 08/6/2026 06:42 PM Eastern

Compare

ARCT vs. ALLO, BBOT, SVA, MDXG, and AVTE

Should you buy Arcturus Therapeutics stock or one of its competitors? MarketBeat compares Arcturus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcturus Therapeutics include Allogene Therapeutics (ALLO), BridgeBio Oncology Therapeutics (BBOT), Sinovac Biotech (SVA), MiMedx Group (MDXG), and Aerovate Therapeutics (AVTE). These companies are all part of the "biotechnology" industry.

How does Arcturus Therapeutics compare to Allogene Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Allogene Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Allogene Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat Allogene Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcturus Therapeutics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$42.35M	4.08	-$65.78M	-$2.81	N/A
Allogene Therapeutics	$20K	33,997.28	-$190.89M	-$0.77	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arcturus Therapeutics has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Arcturus Therapeutics currently has a consensus price target of $24.25, suggesting a potential upside of 298.85%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 332.60%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Arcturus Therapeutics beats Allogene Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arcturus Therapeutics has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Arcturus Therapeutics	$42.35M	4.08	-$65.78M	-$2.81	N/A

BridgeBio Oncology Therapeutics presently has a consensus target price of $24.80, suggesting a potential upside of 182.46%. Arcturus Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

In the previous week, Arcturus Therapeutics had 4 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 1 mentions for BridgeBio Oncology Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcturus Therapeutics beats BridgeBio Oncology Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Sinovac Biotech?

Arcturus Therapeutics (NASDAQ:ARCT) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Sinovac Biotech has higher revenue and earnings than Arcturus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$42.35M	4.08	-$65.78M	-$2.81	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Arcturus Therapeutics presently has a consensus target price of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Arcturus Therapeutics had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 0 mentions for Sinovac Biotech. Arcturus Therapeutics' average media sentiment score of 0.72 beat Sinovac Biotech's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcturus Therapeutics	Positive
Sinovac Biotech	Neutral

Sinovac Biotech has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Sinovac Biotech's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Sinovac Biotech	N/A	N/A	N/A

94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Arcturus Therapeutics beats Sinovac Biotech on 10 of the 15 factors compared between the two stocks.

How does Arcturus Therapeutics compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

MiMedx Group has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market.

In the previous week, MiMedx Group had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat MiMedx Group's score of 0.32 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.46	$48.58M	$0.04	104.50
Arcturus Therapeutics	$42.35M	4.08	-$65.78M	-$2.81	N/A

MiMedx Group has a net margin of 1.76% compared to Arcturus Therapeutics' net margin of -143.80%. MiMedx Group's return on equity of 12.09% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

MiMedx Group presently has a consensus price target of $8.50, suggesting a potential upside of 103.35%. Arcturus Therapeutics has a consensus price target of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MiMedx Group beats Arcturus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Aerovate Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Arcturus Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 0 mentions for Aerovate Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.72 beat Aerovate Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcturus Therapeutics	Positive
Aerovate Therapeutics	Neutral

Arcturus Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$42.35M	4.08	-$65.78M	-$2.81	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Aerovate Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Arcturus Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 298.85%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Arcturus Therapeutics beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$177.93M	$3.61B	$6.95B	$12.87B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-2.16	8.36	271.12	25.30
Price / Sales	4.08	1,290.80	599.80	82.44
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	0.81	17.64	13.00	6.13
Net Income	-$65.78M	-$13.22M	$3.46B	$342.95M
7 Day Performance	5.56%	4.45%	3.39%	3.19%
1 Month Performance	-20.00%	-4.89%	-2.69%	-1.98%
1 Year Performance	-49.25%	56.58%	75.97%	21.11%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.4838 of 5 stars	$6.08 -2.9%	$24.25 +298.8%	-50.2%	$177.93M	$42.35M	N/A	180	Earnings Report
ALLO Allogene Therapeutics	2.3528 of 5 stars	$1.84 -2.1%	$8.52 +363.2%	+85.8%	$648.89M	$20K	N/A	310	Positive News Upcoming Earnings Gap Up
BBOT BridgeBio Oncology Therapeutics	2.0743 of 5 stars	$8.25 +2.0%	$24.80 +200.6%	N/A	$648.07M	N/A	N/A	N/A
SVA Sinovac Biotech	0.2607 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	Upcoming Earnings High Trading Volume
MDXG MiMedx Group	2.9205 of 5 stars	$4.27 +3.4%	$8.50 +99.1%	-42.3%	$601.99M	$418.63M	106.78	870

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. ALLO, BBOT, SVA, MDXG, and AVTE

How does Arcturus Therapeutics compare to Allogene Therapeutics?

Summary

How does Arcturus Therapeutics compare to BridgeBio Oncology Therapeutics?

Summary

How does Arcturus Therapeutics compare to Sinovac Biotech?

Summary

How does Arcturus Therapeutics compare to MiMedx Group?

Summary

How does Arcturus Therapeutics compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. ALLO, BBOT, SVA, MDXG, and AVTE

How does Arcturus Therapeutics compare to Allogene Therapeutics?

Is ARCT or ALLO more profitable?

Does the media favor ARCT or ALLO?

Which has preferable earnings and valuation, ARCT or ALLO?

Do institutionals and insiders hold more shares of ARCT or ALLO?

Which has more risk and volatility, ARCT or ALLO?

Do analysts prefer ARCT or ALLO?

Summary

How does Arcturus Therapeutics compare to BridgeBio Oncology Therapeutics?

Which has more risk and volatility, BBOT or ARCT?

Do insiders & institutionals have more ownership in BBOT or ARCT?

Which has preferable earnings & valuation, BBOT or ARCT?

Do analysts prefer BBOT or ARCT?

Is BBOT or ARCT more profitable?

Does the media prefer BBOT or ARCT?

Summary

How does Arcturus Therapeutics compare to Sinovac Biotech?

Which has higher earnings and valuation, ARCT or SVA?

Do analysts prefer ARCT or SVA?

Does the media prefer ARCT or SVA?

Is ARCT or SVA more profitable?

Do institutionals & insiders have more ownership in ARCT or SVA?

Which has more risk & volatility, ARCT or SVA?

Summary

How does Arcturus Therapeutics compare to MiMedx Group?

Which has more risk & volatility, MDXG or ARCT?

Does the media refer more to MDXG or ARCT?

Which has preferable earnings and valuation, MDXG or ARCT?

Is MDXG or ARCT more profitable?

Do analysts rate MDXG or ARCT?

Do insiders & institutionals hold more shares of MDXG or ARCT?

Summary

How does Arcturus Therapeutics compare to Aerovate Therapeutics?

Which has more risk & volatility, ARCT or AVTE?

Does the media refer more to ARCT or AVTE?

Which has higher earnings & valuation, ARCT or AVTE?

Is ARCT or AVTE more profitable?

Do analysts prefer ARCT or AVTE?

Do insiders and institutionals hold more shares of ARCT or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools